UPMC McKeesport

Abstract Assisted automation of radiation field survey with robots has the potential to increase the efficiency of maintenance in radiation environments, reduce human exposure to harmful radiation fields, accelerate emergency response, and improve anomaly characterization. Algorithms for the control and path planning of these robots need to be accurate, efficient, and interpretable, so human operators can make informed decisions to update the search path on-the-fly. Several approaches have been used to address this problem with Bayesian optimization recently showing promising results. Bayesian optimization has only been demonstrated in relatively simple simulated radiation environments using static measurements which minimize the amount of information collected. In this paper, we expand Bayesian optimization by accounting for dynamic real-time data acquisition to optimize the agents' collection routes. We demonstrate the proposed approach using noisy raw datasets obtained from a real-world radiation environment in three different scenarios combined with a probabilistic model. The radiation data were collected in different room-sized environments, including a research reactor at power with attenuation obstacles, and at significantly different gamma radiation levels. The performance of the dynamic collection scheme is compared with traditional point to point static data collection. It is shown that the addition of dynamic measurements can effectively find at least 10-36% hotter signals and reduce the mean number of loop iterations required to survey the space by up to 70%, depending on scenario. Radiation field reconstruction accuracy is improved considerably, with a 40% reduction in root mean squared error in most cases.

Abstract Date Presented 04/03/2025 This poster provides interventions that female veterans can use to overcome daily challenges. It also establishes a framework for a life skills program that empowers participants to acquire the skills needed for independent living. Primary Author and Speaker: Tarah Marie Barrett Contributing Authors: Christine Daeschner

Abstract Date Presented 04/03/2025 This poster emphasizes the important role OT plays in developing and implementing a fall prevention program in an assisted living facility. This holistic program positively affected the roles, routines, and habits of the residents. Primary Author and Speaker: Katherine Grace Marszalek Contributing Authors: Laura Huth, Christine Daeschner

Alport syndrome (AS) is a genetic disorder characterized by progressive kidney disease, hearing loss, and eye abnormalities. It is caused by mutations in the genes responsible for producing type IV collagen, which is a crucial component of the glomerular basement membrane, the cochlea, and the lens of the eye. We present a case of a 40-year-old female who presented with persistent microscopic hematuria and proteinuria and was diagnosed with autosomal dominant AS based on kidney biopsy and genetic testing. This case report discusses the clinical presentation, diagnostic work-up, and management approach of patients with AS. We highlight the current advancement in management of CKD with SGLT 2 inhibitors, with limited research regarding the benefit of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with genetic disorders like AS. Early recognition and management of AS with ACE inhibitors and SGLT2i are vital to prevent irreversible kidney damage and other complications. Genetic testing and multidisciplinary care play key roles in the treatment of AS.

Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for weight reduction, improved glycaemic control and cardiorenal benefits. However, these medications come with serious adverse events and need closer monitoring once they are initiated. We present a case of a 35-year-old female with no comorbidities taking tirzepatide for weight loss. She developed severe rhabdomyolysis that required hospitalisation; muscle biopsy revealed necrotising myopathy. Her rhabdomyolysis resolved after stopping tirzepatide and conservative management with intravenous fluids. Since no other contributing factor could be identified, we believe tirzepatide may have increased her risk of rhabdomyolysis. In patients presenting with rhabdomyolysis, consideration should be given to GLP-1 agonists as a potential contributing factor for the development of rhabdomyolysis. Clinicians need to be aware of unusual side effects of glucagon-like peptide-1 (GLP-1) agonists like rare occurrence of rhabdomyolysis potentially associated with the use of tirzepatide.Risks versus benefits of these medications should be discussed in detail with patients before prescribing.Close patient follow-up and monitoring for adverse events is necessary, especially after prescribing relatively newer medications such as GLP-1 agonists with evolving knowledge of adverse event profile.

Upper gastrointestinal bleeding (UGIB) in COVID-19 presents challenges in patient management. Existing studies lack comprehensive review due to varied designs, samples, and demographics. A meta-analysis can provide valuable insights into the incidence, features, and outcomes of UGIB in COVID-19. A comprehensive literature search was carried out using several databases. We considered all appropriate observational studies from all over the world. Mantel-Haenszel odds ratios and associated 95% confidence intervals (CIs) were produced to report the overall effect size using random effect models. Besides, Random effects models were used to calculate the overall pooled prevalence. Funnel plots, Egger regression tests, and Begg-Mazumdar's rank correlation test were used to appraise publication bias. Data from 21 articles consisting of 26,933 COVID-19 patients were considered. The pooled estimate of UGIB prevalence in patients admitted with COVID-19 across studies was 2.10% (95% CI, 1.23-3.13). Similarly, the overall pooled estimate for severity, mortality, and rebleeding in COVID-19 patients with UGIB was 55% (95% CI, 37.01-72.68), 29% (95% CI, 19.26-40.20) and 12.7% (95% CI, 7.88-18.42) respectively. Further, UGIB in COVID-19 patients was associated with increased odds of severity (OR=3.52, 95% CI 1.80-6.88, P=0.001) and mortality (OR=2.16, 95% CI 1.33-3.51, P=0.002) compared with patients without UGIB. No significant publication bias was evident in the meta-analysis. The results of our study indicate that UGIB in individuals with COVID-19 is linked to negative outcomes such as severe illness, higher mortality rates, and an increased risk of re-bleeding. These findings highlight the significance of identifying UGIB as a significant complication in COVID-19 cases and emphasise the importance of timely clinical assessment and proper treatment.